Evolva has acquired 2 companies. It has also divested 1 asset.
Evolva’s largest acquisition to date was in 2014, when it acquired Allylix for $46M. Evolva has acquired in 1 US state, and 2 countries. The Company’s most targeted sectors include chemicals (50%) and life science (50%).
Duggingerstrasse 23,
Reinach,
4153
Switzerland,
+41 61 485 2000
www.evolva.com
| Date | Target |
Value
$mlns |
Transaction Type | Acquirer | Seller |
SRC
Link |
|---|---|---|---|---|---|---|
| 2014-12-17 |
Evolva Holding - EV-035 · Life Science
, Switzerland EV-035 is a series of novel small molecule broad spectrum antibiotics of the 4-oxoquinolizine class and targets bacterial type IIa topoisomerase. |
- | Divestiture | - |
Unlimited Searches Unlimited Profile Views Build and Export Lists of
Mergr is a user-friendly database designed to simplify the complex world of private equity and M&A for busy professionals.
We created Mergr to eliminate the challenge of tracking company acquisitions, sales, and ownership, providing clear insights into investment firms and their activities. For example, explore an investment firm’s investment criteria, deal history, portfolio, and connections - organized to help you uncover opportunities and make informed decisions.
With Mergr, gain access to a comprehensive, interconnected web of transactions, investors, companies, and advisors - all in one place.
Full access to Mergr's investor, acquirer, and transaction data starts here.
